Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

By N. Keating, A. O’Malley, M. Smith. Journal of Clinical Oncology, 2006

1,309 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Adverse effects of androgen deprivation therapy and strategies to mitigate them. (2015, methodology): “For example, in both the SEER-Medicare study and the Danish registry study, the excess risk of CV events on ADT was seen only in men receiving GnRH agonists and not in men receiving orchiectomy [32,55], raising the possibility that orchiectomy may be associated with lower CV risk.”
Radiotherapy and short-term androgen deprivation for localized prostate cancer. (2011, neutral): “Not applicable or not answered 13/284 (5) 4/274 (1) 0.”
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence (2014, background): “…include the finding of increased cardiovascular disease and diabetes among men treated with androgen deprivation for localised prostate cancer (Keating et al, 2006), the risks of cardiac disease after radiotherapy for breast cancer (Darby et al, 2013), and long-term toxicities associated with…”